Log In
Print this Print this

Indacaterol/glycopyrronium bromide/mometasone fuorate (QVM149)

  Manage Alerts
Collapse Summary General Information
Company Vectura Group plc
DescriptionOnce-daily combination of indacaterol, a long-acting adrenergic receptor beta 2 agonist (LABA), glycopyrronium bromide, a long-acting muscarinic receptor antagonist (LAMA), and mometasone fuorate, an inhaled corticosteroid (ICS)
Molecular Target Adrenergic receptor beta 2 (ADRB2) ; Muscarinic receptor
Mechanism of ActionAdrenergic receptor beta 2 (ADRB2) agonist; Muscarinic receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationAsthma
Indication DetailsTreat moderate to severe asthma
Regulatory Designation
PartnerNovartis AG;
Sosei Group Corp.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today